CA: A Cancer Journal for Clinicians
Articles in this Issue
Colorectal cancer statistics, 2026
Abstract Colorectal cancer (CRC) is the second most common cancer‐related death in the United States and ranks first in adults younger than 50 years. Every 3 years, the American Canc...
Ethical considerations of genetic and genomic testing in pediatric oncology: A narrative review
Abstract Genomics—and genomic testing in particular—has transformed oncology, facilitating both targeted therapies and personalized care. In pediatric oncology, unique clinical and e...
Radiotherapy followed by adjuvant temozolomide improves survival for patients with aggressive <i>IDH</i> ‐mutated anaplastic glioma
Correction to “American Cancer Society’s report on the status of cancer disparities in the United States, 2025”
Targeting tumor suppressor gene co‐mutations in <i>EGFR</i> ‐mutant nonsmall cell lung cancer: How ACROSS2 sharpens the case for early intensification
Nonpharmacologic interventions for managing distress, anxiety, and depression for patients with cancer and their family caregivers: A systematic review and meta‐analysis
Abstract As more cancer treatments take place in outpatient settings, family caregivers provide essential care and emotional support over long periods. Unaddressed patient and caregi...
Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with <i>EGFR</i> and concomitant tumor suppressor genes (ACROSS2): An open‐label, multicenter, randomized phase 3 study
ABSTRACT Third‐generation epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR‐TKIs) are standard first‐line therapy for advanced,...
Adding carboplatin to sequential taxane–anthracycline neoadjuvant chemotherapy shows improved event‐free and overall survival benefits in premenopausal women with triple‐negative breast cancer
Integrating multimodal management and molecular profiling in a patient with BRAF V600E–positive melanoma and brain metastases
Global cancer statistics for children: Two decades of change and projections to 2050
Abstract Reliable, contemporary estimates of the global childhood cancer burden remain scarce, particularly in the post‐coronavirus disease 2019 (COVID‐19) era. By using data from th...